Table 2.

Demographic and clinical characteristics of patients

Subject	Target	Sex	Age	Disease duration (years)	Age at onset (years)	MDS-UPDRS III pre-DBSa	MDS-UPDRS III post-DBSb	LEDD pre-DBS	LEDD post-DBS	N visits between IP and cFU	cFU: time after implant (months)
1	STN	F	50	17	32	54	18	1186	80	6	9
2	GPi	F	63	17	45	51	42	1185	735	7	13
3	STN	F	58	6	51	42	33	720	270	5	8
4	STN	M	54	9	43	29	17	1520	120	8	16
5	STN	M	62	12	50	46	27	1290	595	5	6
6	GPi	F	70	9	60	38	26	690	450	6	8
7	STN	M	52	14	37	36	23	661	505	7	11
8	GPi	M	45	9	35	84	62	875	325	8	12
9	GPi	F	52	19	12	55	40	550	400	7	12
10	STN	M	56	11	44	61	32	1740	740	7	13
11	GPi	F	64	17	47	56	47	1180	170	4	8
12	STN	F	66	19	46	74	45	917.5	575	6	9
13	STN	M	58	13	45	56	45	1055	400	4	7
14	STN	M	60	12	48	45	31	1327	570	5	7
15	STN	F	53	4	48	29	26	1305	400	5	6
16	STN	F	65	9	56	41	22	700	325	5	6
17	GPi	M	69	23	45	62	43	1113	1008	6	6
18	GPi	M	54	13	41	47	37	850	400	5	8
19	STN	M	47	7	40	40	26	1502	550	4	6
Mean ± SD			55.8 ± 7.5	12.6 ± 5	43.4 ± 10.1	49.8 ± 14.2	33.8 ± 11.6	1071.9 ± 333.3	453.6 ± 228.3	5.7 ± 1.2	9 ± 2.9

^aPerformed before surgery, in the OFF-medication condition.

^bPerformed 1 year after surgery, in the OFF-medication, ON-stimulation condition.

cFU clinical follow-up, LEDD Levodopa Equivalent Daily Dose, IP initial programming, SD standard deviation.